8. Huntington disease Clinical trials / Disease details
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00788047 (ClinicalTrials.gov) | November 2008 | 7/11/2008 | A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan | A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon [PF-01913539] On The Single-Dose Pharmacokinetics Of The CYP2D6 Substrate Dextromethorphan In Healthy Subjects | Huntington Disease;Alzheimer Disease | Drug: Dextromethorphan;Drug: Dimebon + Dextromethorphan | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | Both | 14 | Phase 1 | United States |